Detail akcie Puma online

Business Summary: Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Puma Biotechnology Inc revenues decreased 1% to $228.4M. Net income increased 3% to $31.1M. Revenues reflect Royalty revenue decrease of 31% to $24.3M. Net income reflects Development and commercialization of innovative products segment income increase of 20% to $37.3M. Basic Earnings per Share excluding Extraordinary Items remained flat at $0.62.